Cancer cell regulation

Dr. Salvatore Papa

Honorary Research Fellow Imperial College London & Head of Inflammation and Metabolism Group Institute of Hepatology, London

- The Foundation for Liver Research -

<u>s.papa@imperial.ac.uk</u> or <u>s.papa@researchinliver.org.uk</u>


BSc Gastroenterology (2011-2012) Module 2 - November 18, 2011

What we will discuss


- Cancer: definition, different kinds of cancer,
- From where cancer arise
- Hallmarks of Apoptosis and Necrosis
- Transcription process and Transcription Factors
- NF-κB, IκB, and IKK Protein Families
- Molecular mechanisms by which NF-κB blocks cell death
- New therapies prospects



Different kinds of cancer




Naming cancer






Normal cell growth






Loss of normal cell growth






Example of normal growth



Number of dividing cells in the basal layer = Number of dead cells that are lost from the surface






Artwork by Jeanne Kelly ©2004



The central dogma of Molecular Biology




Transcription Factors: definition

- Transcription factors are proteins involved in the regulation of gene expression that bind to the regulatory regions upstream of genes and either facilitate or inhibit transcription.
- Transcription factors are composed of two essential functional regions:
 - The DNA-binding domain consists of amino acids that recognize specific DNA bases near the start of transcription.
 - The activator domains of transcription factors interact with the components of the transcriptional apparatus (RNA Polymerase) and with other regulatory proteins, thereby affecting the efficiency of DNA binding



Transcription factor: how it works?



1986: discovery of the Nuclear Transcription Factor, NF-\kappaB

Cell, Vol. 47, 921-928, December 26, 1986, Copyright © 1986 by Cell Press

Inducibility of κ Immunoglobulin Enhancer-Binding Protein NF- κ B by a Posttranslational Mechanism

Ranjan Sen and David Baltimore

Whitehead Institute for Biomedical Research Cambridge, Massachusetts 02142 Department of Biology Massachusetts Institute of Technology Cambridge, Massachusetts 02139

Summary

NF- κ B is a nuclear protein, found only in cells that transcribe immunoglobulin light chain genes, that interacts with a defined site in the κ immunoglobulin enhancer. This protein can be induced in pre-B cells by stimulation with bacterial lipopolysaccharide (LPS). The induction involves a posttranslational activation, and the combined action of LPS and cycloheximide causes a superinduction. An active phorbol ester also induces this factor, and with kinetics more reaid than Ephrussi et al. (1985) and Church et al. (1985) have reported in vivo footprinting analysis of a putative B-cellspecific enhancer-binding protein that interacts with the immunoglobulin heavy chain enhancer, and in vitro (Sassone-Corsi et al., 1985) and in vivo experiments (Mercola et al., 1985) have shown that enhancer effects may be competed away by the presence of large excesses of the enhancer sequence.


As a step toward understanding the mechanism of tissue-specific enhancer function, we have recently reported the identification of five factors that interact with the B-cell-specific heavy chain and κ light chain enhancers (Sen and Baltimore, 1986; Staudt et al., 1986; Weinberger et al., 1986; Singh et al., 1986). The most interesting of these factors, NF- κ B, is one that interacts only with the κ enhancer and appears to be stage-specific within the lymphoid lineage, being expressed in mature B cells and plasma cells but not in pre-B cells or T cells (Sen

40,871 articles on the subject NF- $\kappa B_{\mbox{\scriptsize m}}$ and counting: Why then?

S NCBI Resources 🕑 How	v To 🖂			My NCBI Sign In
Pub Med.gov	Search: PubMed	SRSS Save search Limits Advanced search Help		
U.S. National Library of Medicine	NF-kappaB	Search Clear		
National Institutes of Health				
Display Settings: () Summary, 2	0 per page, Sorted by Recently Added		Send to: 🖂	Filter your results:
				All (40871)
Are you looking for gene information? Source: Gene Database				Review (4158)
See 1691 articles about NFKB1 (NFKAPPAB) gene function				Free Full Text (17378)
NFKB1 (NFKAPPAB) nuclea	ar factor of kappa light polypeptide gene e	nhancer in B-cells 1 [Homo sapiens]		Manage Filte
nfkappab in Homo sapiens I M	us musculus Xenopus laevis All 3 Gene record	na de la consecta de Is		1 Second
				Also try:
Results: 1 to 20 of 40871 <pre></pre>				nf-kappab review
				nf-kappab activation
 Identification of novel small molecule activators of nuclear factor-kb with neuroprotective action via high-throughput screening. Manuvakhova MS, Johnson GG, White MC, Ananthan S, Sosa M, Maddox C, McKellip S, Rasmussen L, Wennerberg K, Hobrath JV, White EL, Maddry JA, Grimaldi M. 				nf-kappab pathway
J Neurosci Res. 2010 Nov 2. [Epub ahead of print]				nf-kappab inhibitor
PMID: 21046675 [PubMed - as supplied by publisher]				cancer nf-kappab
The role of tissue trans	dutaminase (TG2) in regulating the tu	mour progression of the mouse colon carcinoma CT26.		
Kotsakis P, Wang Z, Collighan RJ, Griffin M.				Titles with your search terms
	Amino Acids. 2010 Nov 3. [Epub ahead of print] PMID: 21046178 [PubMed - as supplied by publisher]			
PMID: 21046178 [PubMed -	as supplied by publisher]			Is NF-kappaB a good target for cancer therapy' Hopes and pitfalls. [Nat Rev Drug Discov. 200
The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.				SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene express [Cell. 200
Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gregersen H, Nexø BA, Vogel UB.				NF-kappaB signaling, liver disease and hepatoprotective agents. [Oncogene. 200
	Ann Hematol. 2010 Nov 3. [Epub ahead of print]			
PMID: 21046104 [PubMed -	as supplied by publisher]			See more
CXCL12-CXCR4 signal	XCL12-CXCR4 signalling axis confers gemeitabine resistance to pancreatic cancer cells: a novel target for therapy.			
	ngh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP.			6986 free full-text articles in PubMed Central
	Cancer. 2010 Nov 2. [Epub ahead of print] D: 21045835 [PubMed - as supplied by publisher]			Subtoxic levels hydrogen peroxide-induced
1 MID. 21040000 [1 dbMidd -	as adding ny banisher]			production of interleukin-6 by retin [Mol Vis. 201
ISTER AND INCOMES TO A DECIMAL OF A DECIMAL	NAMES OF TAXABLE PARTY OF TAXABLE PARTY OF TAXABLE PARTY.	yunnanensis inhibiting nitric oxide production and NF-KB activation	on.	Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macroph [J Clin Invest. 201
	an JT, Su J, Peng YM, Li Y, Li J, Zhou YB, Zeng GZ, Yan H, Tan NH. ioorg Med Chem. 2010 Oct 31. [Epub ahead of print]			Gene network analysis of bone marrow
PMID: 21044847 [PubMed -				mononuclear cells reveals activ [PLoS One. 201
				See all (6986
		in contributes to apoptosis and chemo-sensitizing effect in Ramos	cells.	
 Nazari M, Ghorbani A, F Eur J Pharmacol. 2010 Oct 3 	lekmat-Doost A, Jeddi-Tehrani M, Zano 30, [Epub ahead of print]	іп.		Find related data
PMID: 21044621 [PubMed - as supplied by publisher]				Database: Select
O Otimulatany Effect of L	R and Faadhack Effact of DOCO	97 production		
	S and Feedback Effect of PGE2 on IL R. Song Y. Liu WY. Pan F. Li Y. Zhu Y.			(Find items)



<u>Nuclear Factor-kappa B</u> (NF- κ B) protein family






NF- κ B: assembling details

The term NF- κ B refers to a family of inducible dimeric transcription factors that recognize a common sequence motif, the " κ B site"


The possible dimeric combination are:








$\textbf{NF-} \textbf{\kappa} \textbf{B: assembling details}$






Inhibitor-kappa B (I κ B) proteins family







Inhibitor-kappaB kinase (IKK) proteins family



The classical NF- κ B pathway




The alternative NF- κ B pathway



Bonizzi G and Karin M (2004). Trends Immunol 25: 280-288



The pro-survival activity of NF- κB






What is Programmed Cell Death (PCD)?

An important mechanism in both development and homeostasis in adult tissue for removal of either superfluous, infected, transformed or damaged cells by activation of an intrinsic suicide program

Programmed Cell Death


Apoptosis



versus

- Energy-dependent Process
- Suppression of Inflammation
- Plasma membrane integrity maintained
- Order DNA fragmentation
- Cell first shrink, nuclei condense formation of '*apoptotic bodies*'





- Energy-independent Process
- Induction of Inflammation
- Plasma membrane integrity lost
- Random DNA fragmentation
- Cell swells, ruptures during demise
 Releasing of cellular contents

Biological roles of the pro-survival activity of NF- κB

- Cellular Responses to the Triggering of
- TNF-Rs, TRAIL-Rs and Fas
- B Lymphopoiesis
- Bone Morphogenesis
- B- and T-Cell Costimulation (CD40, CD28, etc.)
- Liver Development


The pro-survival activity of NF- κB in disease

- Cellular Responses to the Triggering of
- TNF-Rs, TRAIL-Rs and Fas
- B Lymphopoiesis
- Bone Morphogenesis
- B- and T-Cell Costimulation (CD40, CD28, etc.)
- Liver Development

- Cancer
- Cancer chemo- and radio-resistance
- Chronic inflammatory disease (IBD, RA)
- Metabolic & vascular disorder (atherosclerosis)



$NF-\kappa B$ in cancer



Role of the NF- κB pro-survival activity in cancer

- Suppression of Transformation
 - Associated Apoptosis:
- Survival of Late Stage Tumors:
- oncogenic Ras, Bcr-Abl, etc.
- Hodgkin's Lymphoma
- Breast Cancer
- Diffuse Large B Cell Lymphoma
- Multiple Myeloma
- Colon Cancer
- Prostate Cancer
- Burkitt's Lymphoma
- Resistance to Anti-Cancer Therapy:
 - Ionizing Radiation
 - Topoisomerase Inhibitors
 - Cisplatinum



Summary: part 1


- NF-κB are transcription factors that block Programmed Cell Death (PCD)
- Apoptosis and necrosis are two forms of PCD
- Deregulation of the ability of NF-κB to control PCD leads to oncogenesis




What is the molecular mechanism by which NF- κ B control Programmed Cell Death?



TNF-R1 signalling



TNF-R1 signalling



Protein kinase: definition


A kinase is an enzyme that modifies other proteins by adding phosphate groups (phosphorylation).

Phosphorylation usually results in a functional change of the target protein (substrate).


The activity of a kinase involves removing a phosphate group from ATP and covalently attaching it to an amino acids that have a free hydroxyl group.

Most kinases act on both serine and threonine, others act on tyrosine.

By contrast, phosphatase is an enzyme that removes a phosphate group from its substrate.



Distinct mechanisma of PCD inhibition



$\textbf{Gadd45}\beta/\textbf{Myd118}$

- ~21 kDa
- Predominantly Nuclear
- Member of the Gadd45 Family of Inducible Factors,
- Also Including Gadd45 α and Gadd45 γ
- Proposed Functions of Gadd45β:
- Specific inhibitor of JNK cascade
- Ectopic expression of Gadd45 β inhibits the
- JNK-mediated PCD downstream of TNFR




Gadd45 β interact with MKK7

Active MKK7 MKK7 K149


Inactive MKK7




Gadd45 β bind the ATP-binding site of MKK7



Peptides (P1) disrupting Gadd45 β /MKK7 interaction restores MKK7 activity




Cell-permeable Peptide 1 (P1) prevents inhibition of TNF α -induced apotosis



NF- κ B-null cells over-expressing Gadd45 β

NB: Cell treatment with Peptide 1 induce death in cells otherwise resistant to death-signal

Summary: part 2





Why study molecular mechanisms by which NF-ĸB blocks PCD are important ???

$\text{NF-}\kappa\text{B}$ blockers as pharmacological compound

TNFα Cancer, Chronic Inflammation NF-κB NF-κB blockers (salicylates, prot. inhibitors, glucorticoids)


anti-TNF α Abs

Inhibition of NF-kB by either glucocorticoids or proteasome inhibitors is beneficial in certain malignancies, including HL and MM.

However, current compounds can only achieve partial inhibition of NF-κB and have considerable side effects, which limit their use in humans.

Immunity

Future therapies: Gadd45 β and FHC may represent new targets



Conclusions

- NF-κB are transcription factors that block Programmed Cell Death (PCD)
- Apoptosis and necrosis are two forms of PCD
- Deregulation of the ability of NF-κB to control PCD leads to oncogenesis
- Downstream TNFR1, Gadd45β□is up-regulated by NF-κB and inhibits JNK pathway by blocking MKK7
- New anticancer therapy can be developed based on inhibitors of Gadd45β–MKK7 interaction (?)

Learning outcomes

- Describe the NF-kB signalling
 - Defined protein families

The key molecular events and molecules involved in its activation

- Compare the morphological changes and the different host response to the two forms PCD
- List the genes that are induced by NF-κB in response to TNFa
- Describe one of the molecular mechanism by which NF- κ B blocks PCD

Draw the JNK pathway

 Relate the survival activity of NF-κB to the therapeutic potential of its inhibition in cancer and the possible complications

References

- Baud V and Karin M. (2009). Is NF-κB a good target for cancer therapy? Hopes and pitfalls. <u>Nature</u>, 8:33-40.
- Ghosh S, and Hayden MS. (2008). New regulators of NF-κB in inflammation. <u>Nat.</u> <u>Rev. Immunology</u>, 8:837-848.
- Staudt L. (2010). Oncogenic activation of NF-κB. Cold Spring Harb. Perspect. Biol., 2:a000109.
- Papa S, Zazzeroni F, Bubici C et al Franzoso G. (2004). Gadd45b mediates the NFκB suppression of JNK signalling by targeting MKK7/JNKK2. <u>Nat. Cell Biol</u>, 6: 146-153.
- Rock KL & Kono H (2008). The inflammatory Response to cell Death. <u>Annu.Rev.Pathol.Mech.Dis.</u>, 3: 99-126.
- Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, Dean K, Franzoso G. (2006). The NF-κB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. <u>Cell Death Differ</u>, 13: 712-729